PROFIL PENGGUNAAN CHOP DAN RCHOP PADA PASIEN LIMFOMA NON-HODGKIN DI RSUP DR. SARDJITO
DOI:
https://doi.org/10.36387/jifi.v8i1.2529Keywords:
Non-Hodgkin lymphoma, CHOP, R-CHOP, patient characteristicsAbstract
Non-Hodgkin lymphoma (LNH) is a heterogeneous malignancy of the lymphatic system with CHOP and RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone) chemotherapy regimens as main options. Local data on patient characteristics undergoing these treatments are still limited, especially at Dr. Sardjito General Hospital. This study evaluates the characteristics of LNH patients receiving both regimens at Dr. Sardjito (2020–2023). It is a descriptive observational study with a cross-sectional design. Data from patient medical records were analyzed descriptively. Of 176 patients, 80 received CHOP and 96 R-CHOP. Most were male (CHOP: 70%; R-CHOP: 60.4%) and aged >50 years, with peak age of 51–60 in CHOP (40%) and >60 in R-CHOP (44.8%). Comorbidities were found in one-third of patients. Advanced stage predominated (CHOP: 31.3% stage 4; R-CHOP: 38.5% stage 2), and most completed 6 chemotherapy cycles. Rituximab ≥550 mg was widely used in R-CHOP; cyclophosphamide >1100 mg, doxorubicin 70–79 mg, and vincristine ≥2 mg were standard in both regimens. Prednisone 100 mg was common. Diffuse Large B-Cell Lymphoma (DLBCL) dominated R-CHOP (98.96%), while CHOP patients included DLBCL (38.75%), FL, PTCL-NOS, and others. Findings highlight the importance of individualized treatment based on histopathology and disease stage.
References
1. Hao C, Zhang N, Geng M, Ren Q, Li Y, Wang Y, et al. Clinical significance of TIPE2 protein upregulation in non-Hodgkin’s lymphoma. J Histochem Cytochem . 2016;64(9):556–64. Available from: http://dx.doi.org/10.1369/0022155416662262
2. Pearce L. Non-Hodgkin’s lymphoma. Nurs Stand . 2016;31(3):15. Available from: http://dx.doi.org/10.7748/ns.31.3.15.s16
3. Komite Penanggulangan Nasional Kanker. PANDUAN PENATALAKSANAAN LIMFOMA NON-HODGKIN. Kementerian Kesehatan Republik Indonesia; 2015.
4. Limfoma Non-Hodgkin: Gejala, Jenis & Pengobatan . [cited 2025 Apr 22]. Available from: https://my.clevelandclinic.org/health/diseases/15662-non-hodgkin-lymphoma
5. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin . 2025 Jan 16 [cited 2025 Mar 16]; Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2025-cancer-facts-figures.html
6. Global Cancer Observatory . [cited 2025 Mar 16]. Available from: https://gco.iarc.fr/en
7. Kementerian Kesehatan RI. Data dan Kondisi Penyakit Limfoma di Indonesia. Pusat Data Dan Informasi Kementerian KesehatanR. Indonesia; 2015.
8. Coleman M, Lammers PE, Ciceri F, Jacobs IA. Role of rituximab and rituximab biosimilars in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk . 2016;16(4):175–81. Available from: http://dx.doi.org/10.1016/j.clml.2016.01.004
9. Ryan RJH, Wilcox RA. Ontogeny, genetics, molecular biology, and classification of B- and T-cell non-Hodgkin lymphoma. Hematol Oncol Clin North Am . 2019;33(4):553–74. Available from: http://dx.doi.org/10.1016/j.hoc.2019.04.003
10. Maeda K, Shibutani M, Otani H, Nagahara H, Ikeya T, Iseki Y, et al. Inflammation-based factors and prognosis in patients with colorectal cancer. World J Gastrointest Oncol . 2015;7(8):111–7. Available from: http://dx.doi.org/10.4251/wjgo.v7.i8.111
11. Painschab MS, Kohler R, Kimani S, Mhango W, Kaimila B, Zuze T, et al. Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis. Lancet Glob Health . 2021;9(9):e1305–13. Available from: http://dx.doi.org/10.1016/S2214-109X(21)00261-8
12. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med . 2002;346(4):235–42. Available from: http://dx.doi.org/10.1056/NEJMoa011795
13. Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH, et al. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. J Korean Med Sci . 2014;29(11):1493–500. Available from: http://dx.doi.org/10.3346/jkms.2014.29.11.1493
14. Salma RS, Sedana MP, Yudho SU. CHOP and R-CHOP therapeutic responses in Non-Hodgkin Lymphoma patients in Dr. Soetomo general hospital Surabaya. Biomolecular and Health Science Journal . 2018;1(2):93. Available from: http://dx.doi.org/10.20473/bhsj.v1i2.9244
15. Morrison VA, Picozzi V, Scott S, Pohlman B, Dickman E, Lee M, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma . 2001;2(1):47–56. Available from: http://dx.doi.org/10.3816/clm.2001.n.011
16. Christine G, Sukrisman L, Sutandyo N, Rumende CM. Rasio Neutrofil Limfosit sebagai Prediktor Neutropenia Akut Awitan Pertama Pascakemoterapi R-CHOP pada Pasien Diffuse Large B-cell Lymphoma. Jurnal penyakit dalam Indonesia . 2019;6(3):115. Available from: http://dx.doi.org/10.7454/jpdi.v6i3.340
17. Susanti WL, Nurrochmad A, Murwanti R. Perbandingan Kemoterapi Chop dan Rchop Terhadap Kejadian Anemia pada Pasien Kanker Limfoma Non-Hodgkin. | Majalah Farmaseutik. 2023;19(2):289–96.
18. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med . 2002;346(4):235–42. Available from: http://dx.doi.org/10.1056/NEJMoa011795
19. Moreno A, Colon-Otero G, Solberg Jr LA. The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin’s lymphomas (NHL): is there a standard? Oncologist . 2000;5(3):238–49. Available from: http://dx.doi.org/10.1634/theoncologist.5-3-238
20. NHS England » Cancer . [cited 2025 Apr 22]. Available from: https://www.england.nhs.uk/cancer/
21. NHS South West Strategic Clinical Network. (R)CHOP regimen: Quick Reference Guide . United Kingdom: NHS; 2020 [cited 2025 Apr 22]. Available from: https://swagcanceralliance.nhs.uk/wp-content/uploads/2020/10/R-CHOP.pdf
22. Maharani Tasyandita R, Yulianti H, Suryawathy Hernowo B. Clinical and histopathological features of non-Hodgkin lymphoma in gastrointestinal system at RSUP Dr. Hasan Sadikin Bandung 2018-2020. Majalah Patologi Indonesia . 2023;32(1). Available from: http://dx.doi.org/10.55816/mpi.v32i1.562
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Jurnal Insan Farmasi Indonesia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
